Home >> Oncology/Hematology >> Oncology/Hematology >> Baked Goods >> Technology & Media >>

Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023

Published: Nov-2014 | Format: PDF | GlobalData | Number of pages: 58 | Code: MRS - 3106


GlobalData has released its new PharmaPoint Drug Evaluation report, “Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Amgen/Takeda’s EGFR antagonist Vectibix (panitumumab) was approved in the US in 2006 as a monotherapy for chemotherapy-refractory, EGFR-expressing, KRAS wild-type metastatic CRC. EU approval followed in 2007, where the agent is also indicated as a treatment for chemotherapy-refractory KRAS wild-type CRC patients, however, EGFR-expression is not specified. Additionally in the EU, the antibody is approved in combination with FOLFOX in the first-line setting, and with FOLFIRI in the second-line setting after progression on a 5-FU regimen. In April 2014, the EU label for Vectibix was updated to specify RAS wild-type disease rather than KRAS.


- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Vectibix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Vectibix for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Vectibix performance
- Obtain sales forecast for Vectibix from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1 Table of Contents 6
1.1 List of Tables 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Screening and Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 25
5 Competitive Assessment 32
5.1 Overview 32
6 Vectibix (panitumumab) 34
6.1 Overview 34
6.2 Efficacy 36
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 37
7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 45
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Diagnosed Colorectal Cancer Patients 48
7.4.2 Percent Drug-Treated Patients 49
7.4.3 General Pricing Assumptions 49
7.4.4 Average Body Weight and Surface Area Across the 8MM 50
7.4.5 Individual Drug Assumptions 51
7.4.6 Generic Erosion 51
7.5 Primary Research - KOLs Interviewed for this Report 52
7.6 Primary Research - Prescriber Survey 54
7.7 About the Authors 55
7.7.1 Analyst 55
7.7.2 Global Head of Healthcare 56
7.8 About GlobalData 57
7.9 Disclaimer 57

List of Tables

Table 1: TNM and Staging Classification System for CRC 16
Table 2: Symptoms of Colorectal Cancer 17
Table 3: Treatment Guidelines for CRC 22
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 23
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 24
Table 6: Leading Treatments for CRC, 2014 33
Table 7: Product Profile - Vectibix 35
Table 8: Vectibix SWOT Analysis, 2014 37
Table 9: Global Sales Forecast ($m) for Vectibix, 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 50
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 54

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3495 View Pricing